ArticleCureus2025
Posterior Reversible Encephalopathy Syndrome as a Complication of Essential Thrombocythemia: A Case Report and Literature Review.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Posterior reversible encephalopathy syndrome (PRES) is a well-defined clinicoradiological syndrome that can arise in various clinical settings, most commonly in association with hypertensive states. However, less typical causes, including hematologic disorders, have also been reported. A 47-year-old male with CALR-mutated essential thrombocythemia (ET) on chronic aspirin therapy developed progressive headache, drowsiness, nausea, and blindness. Workup revealed worsening thrombocytosis (1,250 × 10⁹/L) with unremarkable blood pressure, craniocervical AngioTac, and systemic assessment. PRES secondary to ET exacerbation was suspected. Hydroxyurea was initiated, leading to platelet reduction and symptom improvement. Brain MRI showed bilateral parieto-occipital Fluid-Attenuated Inversion Recovery (FLAIR) hyperintensities. At four months, only mild visual disturbances persisted, with follow-up MRI showing near-complete resolution. ET decompensation may trigger PRES even with normal blood pressure, highlighting the importance of platelet monitoring to prevent complications. All reported cases involved middle-aged males with severe thrombocytosis (>700 × 10⁹/L) and symptom resolution following ET treatment and platelet reduction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.